CN1091635A - 作为具有抗郁作用药物的2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑应用 - Google Patents

作为具有抗郁作用药物的2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑应用 Download PDF

Info

Publication number
CN1091635A
CN1091635A CN93120080A CN93120080A CN1091635A CN 1091635 A CN1091635 A CN 1091635A CN 93120080 A CN93120080 A CN 93120080A CN 93120080 A CN93120080 A CN 93120080A CN 1091635 A CN1091635 A CN 1091635A
Authority
CN
China
Prior art keywords
amino
pyl
pro
tetrahydro benzothiazol
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN93120080A
Other languages
English (en)
Other versions
CN1052400C (zh
Inventor
鲁道夫·汉默
约池穆·米苏
艾理克·来荷
佛兰科·柏斯尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim GmbH
Publication of CN1091635A publication Critical patent/CN1091635A/zh
Application granted granted Critical
Publication of CN1052400C publication Critical patent/CN1052400C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及Pramipcxol作为具有抗抑郁作用的 药物的应用。

Description

本发明涉及2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑,尤其是它的(-)-对映体,以及其药理相容的酸加成盐作为具有抗抑郁作用药物的应用。
所述的化合物作为药物是已知的,其中治疗精神分裂症和治疗帕金森氏病居于首要地位。这种化合物,即在文献中也称作SND919或Pramipexol的其(-)-对映体的,其制备细节从欧洲专利申请EP-A85116016可以得知。现在令人惊奇地发现,Pramipexol具有抗抑郁性能。在这方面特别重要的意义是,该化合物具有意外小的a-受体亲合力,并因而在良好的相容性下有高的选择作用。迄今不曾知道Pramipexol具有长的作用持续时间(半值期12.5小时)和意料不到的超过80%的高生物可利用率,这表明在作为抗抑郁药时具有独特的优点。
Pramipexol的抗抑郁作用在“强迫游泳试验”的临床研究中已得到证实。这种相关试验的细节例如在Willner,Psychopharmacology(精神药理学)83,1-16(1984)以及Borsini和Meli,Psychopharmacology        94,147-160(1988)中已有描述。
已经对8只小鼠进行过Pramipexol(SND919)与阿米庚酸-一种已知的抗郁药的对比试验。将两种物质溶于生理盐水中,并经非肠胃给药。结果示于表1中。
表1        在“强迫游泳试验”中对SND919和
阿米庚酸的试验
化合物        剂量        稳定性时间
mg/kg        (秒)
食盐溶液        -        208±10
SND    919        0.03        210±14
SND    919        0.10        165±6
SND    919        0.30        102±17
阿米庚酸        20.00        134±19
这些结果证明SND        919与阿米庚酸相比有明显的优越性。
Pramipexol可以按通常的盖仑制剂形式配制而用于治疗抑郁症,这种制剂基本上由一种惰性的药物用载体和一种有效剂量的有效物质组成,例如像片剂、糖衣丸、胶囊、淀粉胶囊、粉剂、液剂、悬浮液剂、乳剂、糖浆、栓剂等等。按本发明治疗有效的一次剂量是在0.1和30mg之间,尤其是在1和5mg之间。除了口服或静脉给药之外,Pramipexol也可以按另一种方式使用。在这方面合适的释放体系由现有技术是已知的,例如由欧洲专利申请428038中。
实施例1
含有5mg        2-氨基-6-正丙基-氨基-4,5,6,7-四氢-苯并噻唑-二氢氯化物的糖化丸
组成:
1个糖衣丸核含有:
SND        919        5.0mg
乳糖        33.5mg
玉米淀粉        10.0mg
明胶        1.0mg
硬脂酸镁        0.5mg
50.0mg
制备方法
将有效物质与乳糖和玉米淀粉所形成的混合物用10%的明胶水溶液通过具有1mm筛孔大小的筛网而形成颗粒,在40℃干燥,并且再通过上述筛网磨碎。将如此得到的颗粒产物与硬脂酸镁混合并压制成糖衣丸核。这种制备必须在暗室中进行。
核重:        50mg
阴模:        5mm,成拱形
将如此得到的糖衣丸核按照已知方法用糖衣包上,这种糖衣基本上由糖和滑石粉组成。将完成的糖衣丸用蜂蜡打光。
糖衣丸重:        100mg
实施例2
含有5mg        2-氨基-6-正丙基-氨基-4,5,6,7-四氢-苯并噻唑-二氢氯化物的滴液
组成:
100mlg滴液物质含有:
对羟基苯甲酸甲酯        0.035g
对羟基苯甲酸正丙酯        0.015g
茴香油        0.05g
薄荷醇        0.06g
纯乙醇        10.0g
SND        919        0.5g
柠檬酸        0.7g
磷酸钠(带有×2H2O) 0.3g
环己基氨基磺酸钠        1.0g
甘油        15.0g
蒸馏水        加到100.0ml
制造方法
将对羟基苯甲酸酯、茴香油和薄荷醇溶解在乙醇中(溶液Ⅰ)。使缓冲物质、有效物质和环己基氨基磺酸钠溶解在蒸馏水中并加入甘油(溶液Ⅱ)。将溶液Ⅰ拌合到溶液Ⅱ中,并且用蒸馏水将混合物补足到给定体积。将已制成的滴液用一个合适的滤器过滤。滴液的制备和灌装必须在蔽光和保护气氛下进行。
实施例3
含有10mg        2-氨基-6-正丙基-氨基-4,5,6,7-四氢-苯并噻唑-二氢氯化物的栓剂
1个栓剂含有:
SND        919        10.0mg
栓剂物质(例如Witepsol        W        45)        1690.0mg
1700.0mg
制备方法
将细粉化的物质通过一个浸渍均浆器拌合到已熔化并冷却到40℃的栓剂物料中。将这些物料灌注入稍微预冷到35℃的模中。
栓剂重:        1.7g
实施例例4
含有5mg        2-氨基-6-正丙基-氨基-4,5,6,7-四氢-苯并噻唑-二氢氯化物的安瓿剂
1个安瓿剂含有:
SND        919        5.0mg
柠檬酸        7.0mg
磷酸钠(带有×2H2O) 3.0mg
焦亚硫酸钠        1.0mg
蒸馏水        加到1.0ml
制备方法
将缓冲物质、有效物质和焦亚硫酸钠依次溶于煮沸的并在CO2气氛下冷却的水中。用煮沸过的水补足到给定体积并在非热状态下过滤。
灌装:在保护气氛下灌入褐色安瓿中
灭菌:在120℃下20分钟
安瓿液的制备和灌装必须在暗室中进行。
实施例5
含有10mg        2-氨基-6-正丙基-氨基-4,5,6,7-四氢-苯并噻唑-二氢氯化物的糖衣丸
1个糖衣丸含有:
SND        919        10.0mg
乳糖        35.5mg
玉米淀粉        12.0mg
明胶        1.0mg
硬脂酸镁        0.5mg
59mg
制备方法
类似实施例1。

Claims (4)

1、2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑及其药理相容的酸加成盐在治疗抑郁症中的应用。
2、(-)-2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑及其药理相容的酸加成盐作为具有抗抑郁作用药物的应用。
3、2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑及其药理相容的酸加成盐用于制备治疗抑郁症药物的应用。
4、(-)-2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑及其药理相容的酸加成盐用于制造治疗抑郁症药物的应用。
CN93120080A 1992-12-05 1993-12-04 2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑在制备治疗抑郁症药物中的应用 Expired - Lifetime CN1052400C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4241013A DE4241013A1 (de) 1992-12-05 1992-12-05 Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
DEP4241013.4 1992-12-05

Publications (2)

Publication Number Publication Date
CN1091635A true CN1091635A (zh) 1994-09-07
CN1052400C CN1052400C (zh) 2000-05-17

Family

ID=6474503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120080A Expired - Lifetime CN1052400C (zh) 1992-12-05 1993-12-04 2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑在制备治疗抑郁症药物中的应用

Country Status (29)

Country Link
US (1) US6191153B1 (zh)
EP (1) EP0675717B1 (zh)
JP (1) JP3221880B2 (zh)
KR (1) KR100311165B1 (zh)
CN (1) CN1052400C (zh)
AT (1) ATE183091T1 (zh)
AU (1) AU674378B2 (zh)
BG (1) BG62475B1 (zh)
CA (1) CA2150131C (zh)
CZ (1) CZ282679B6 (zh)
DE (2) DE4241013A1 (zh)
DK (1) DK0675717T3 (zh)
ES (1) ES2136725T3 (zh)
FI (1) FI952734A (zh)
GR (1) GR3031521T3 (zh)
HK (1) HK1019003A1 (zh)
HU (1) HU221014B1 (zh)
IL (1) IL107870A (zh)
MX (1) MX9307644A (zh)
NO (1) NO306930B1 (zh)
NZ (1) NZ258876A (zh)
PL (1) PL309282A1 (zh)
RU (1) RU2157685C2 (zh)
SG (1) SG49228A1 (zh)
SK (1) SK281441B6 (zh)
TW (1) TW362973B (zh)
UA (1) UA35604C2 (zh)
WO (1) WO1994013287A1 (zh)
ZA (1) ZA939065B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028464A (zh) * 2019-04-26 2019-07-19 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
EP1303502A2 (en) * 2000-07-06 2003-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Tetrahydrobenzothiazole analogues as neuroprotective agents
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
EP1260221A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
PE20040134A1 (es) * 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
DE102004006808A1 (de) * 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
WO2006015943A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
UA93608C2 (ru) * 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
EP1867641A4 (en) * 2005-04-04 2010-01-13 Takeda Pharmaceutical A PROPHYLACTIC OR THERAPEUTIC MEDICINE AGAINST AQUEOUS DEPRESSION OR NEUROSIS
JP2009511618A (ja) * 2005-10-18 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
MX2019012088A (es) * 2017-04-10 2020-02-07 Chase Therapeutics Corp Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.
EP3645120A4 (en) * 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
CN108802584B (zh) * 2018-06-29 2020-12-08 广东工业大学 一种变压器绝缘纸老化状态评估方法
TWI672472B (zh) * 2018-08-15 2019-09-21 鄭映芳 飲料製冰機裝置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3930282A1 (de) * 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028464A (zh) * 2019-04-26 2019-07-19 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Also Published As

Publication number Publication date
RU2157685C2 (ru) 2000-10-20
NO952207L (no) 1995-06-02
UA35604C2 (uk) 2001-04-16
FI952734A0 (fi) 1995-06-05
CN1052400C (zh) 2000-05-17
KR950703953A (ko) 1995-11-17
WO1994013287A1 (de) 1994-06-23
ES2136725T3 (es) 1999-12-01
DE4241013A1 (de) 1994-06-09
AU5715294A (en) 1994-07-04
CA2150131A1 (en) 1994-06-23
GR3031521T3 (en) 2000-01-31
JP3221880B2 (ja) 2001-10-22
IL107870A0 (en) 1994-04-12
BG99700A (bg) 1996-04-30
CZ144095A3 (en) 1996-03-13
MX9307644A (es) 1994-06-30
BG62475B1 (bg) 1999-12-30
HU221014B1 (hu) 2002-07-29
FI952734A (fi) 1995-06-05
ATE183091T1 (de) 1999-08-15
NO952207D0 (no) 1995-06-02
NO306930B1 (no) 2000-01-17
IL107870A (en) 1996-12-05
AU674378B2 (en) 1996-12-19
SK281441B6 (sk) 2001-03-12
HUT71798A (en) 1996-02-28
NZ258876A (en) 1997-07-27
DE59309733D1 (de) 1999-09-16
TW362973B (en) 1999-07-01
KR100311165B1 (ko) 2001-12-28
PL309282A1 (en) 1995-10-02
DK0675717T3 (da) 2000-02-28
US6191153B1 (en) 2001-02-20
ZA939065B (en) 1994-08-04
HU9501623D0 (en) 1995-08-28
CA2150131C (en) 2004-09-21
HK1019003A1 (en) 2000-01-14
SG49228A1 (en) 1998-05-18
EP0675717A1 (de) 1995-10-11
JPH08504201A (ja) 1996-05-07
CZ282679B6 (cs) 1997-08-13
EP0675717B1 (de) 1999-08-11
SK74095A3 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
CN1052400C (zh) 2-氨基-6-正丙基-氨基-4,5,6,7-四氢苯并噻唑在制备治疗抑郁症药物中的应用
CN1151785C (zh) 含有二甲双胍和贝特联合的药物组合物及其在制备降低高血糖药物中的应用
CN1440745A (zh) 氟西汀药物制剂
CN1105561A (zh) 治疗酗酒不适的治疗组合物及其使用方法
CN101073563A (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
CN1546008A (zh) 盐酸氨溴索液体缓释制剂及其制备方法
CN1083260C (zh) 用于制备主要活性成分为乙酰水杨酸和灭吐灵的联合体的稳定粉剂的新药物组合物
CN1111405C (zh) 吡拉西坦在制备预防和预防颅内压增高药物中的应用
CN1720948A (zh) 红茴香滴丸及其制备方法
CN1686484A (zh) 银菊清咽滴丸及其制备方法
CN1231223C (zh) 灯盏花素输液制剂及其制备方法
CN1965878A (zh) 含乙酰谷酰胺和红花有效成分的药物组合物及其制剂
CN1250208C (zh) 氟西汀肠溶片
CN1241558C (zh) 阿替洛尔滴丸及其制备方法
CN1430981A (zh) 抗病毒药莪术油制剂及其制备方法
CN1615871A (zh) 加替沙星静脉输注制剂及其制备方法
CN101073572A (zh) 一种治疗风寒湿痹症的药物组合物及其制备方法
CN1575796A (zh) 磷酸川芎嗪滴丸及其制备方法
CN1616102A (zh) 治疗感冒的复方干混悬剂及其处方和制备方法
CN1307981C (zh) 一种具有止血作用的血宁滴丸及其制备方法
CN1618427A (zh) 阿昔洛韦药物树脂生物粘附缓释液体制剂及其制备方法
CN1788738A (zh) 一种含挥发油的药物制剂及其制备方法
CN1272015C (zh) 阿德福韦酯和聚乙二醇共融物及其制备方法
CN1287771C (zh) 杏仁止咳滴丸及其制备方法
CN1679675A (zh) 一种具有清热解毒作用的穿黄消炎滴丸及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20131204

Granted publication date: 20000517